Oncology | pharmaphorum

Skip to main content

Sunday 22 February 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Oncology

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Debates & Insight

Market access webinar Widescreen size NEW v6

Sponsored

Available on demand: Cancer Treatment Access: Strategy, Appr...

Available on demand: A one-hour live debate on Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes.

Views & Analysis

UK-Oncology-Forum-panel-debate

Cancer central to ‘Question Time’-style debate

Topics, ranging from the seven-days- a-week NHS to Brexit, were on the oncology panel's agenda.

News

Cancer-cell

UK trailing Europe on access to cancer drugs - report

UK has some of the lowest uptake of new cancer drugs.

News

iStock_67821339_MEDIUM 1

NICE recommends BMS melanoma combination

NICE makes swift decision on skin cancer treatment.

News

French pharma company Sanofi

Sanofi pushes on with Medivation takeover attempt

French firm is attempting to oust Medivation's board.

News

Blood-generic-2

Pfizer's antibody drug trial misses key survival target in A...

Inotuzumab ozogamicin missed one of two endpoints in trial.

Load more results

Editor's Picks

Hudson out at Sanofi, as Belén Garijo named CEO

Lilly strikes $8.8bn-plus alliance with China's Innovent

Euro VCs team up to invigorate life sciences ecosystem

Moderna cries foul as FDA blocks filing of mRNA flu shot

Novo Nordisk rises as Hims & Hers backs down on oral GLP-1

News

Bone structure

FDA starts review of Regeneron's drug for rare disease FOP

Can Regeneron's drug for ultra-rare bone disease FOP pick up the baton from Ipsen's Sohonos, whose growth has stalled?

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company